Management of Hypertension in CKD Stage 4

Blood Pressure Targets

The American Heart Association recommends a blood pressure target of <140/90 mmHg for patients with CKD stage 4, with a strength of evidence graded as moderate 1, 2, 4, 5
There is insufficient high-quality data for specific BP targets in advanced CKD (stages 4-5) as most major trials, including SPRINT, excluded patients with advanced CKD, highlighting the need for further research 1, 3, 6
The Blood Pressure Control for Renoprotection in Patients With Non-Diabetic Chronic Renal Disease (REIN-2) trial, one of the few trials including CKD stage 4 patients, was stopped early for futility, indicating the challenges of managing hypertension in this population 1, 3
Caution is warranted with intensive BP lowering in advanced CKD as the risk of acute kidney injury is higher than in earlier CKD stages, emphasizing the importance of careful monitoring 1, 3

The American College of Cardiology recommends ACE inhibitors or ARBs as preferred agents for patients with CKD, with a moderate strength of evidence for ACE inhibitors and a weak recommendation for ARBs 1, 2, 4, 5, 6
For patients with albuminuria ≥300 mg/day, ACE inhibitors or ARBs are particularly beneficial, reducing the risk of progression to end-stage renal disease 2, 7, 8
When starting ACE inhibitors or ARBs, serum creatinine may increase up to 30% due to reduction in intraglomerular pressure, which is expected and should be monitored closely 7

Calcium channel blockers (CCBs) are a viable option for BP reduction in advanced CKD, particularly in patients who cannot tolerate ACE inhibitors or ARBs 3, 6
Loop diuretics are effective for volume control in advanced CKD, and should be used judiciously to avoid dehydration and electrolyte imbalances 3, 6
For black patients with CKD, initial therapy should include a thiazide diuretic or calcium channel blocker, with an ACE inhibitor or ARB added if proteinuria is present, highlighting the importance of tailored treatment approaches 4, 5, 8

In CKD stages 4-5, the risk of AKI with intensive BP lowering is higher than in earlier CKD stages, emphasizing the need for careful monitoring and individualized treatment plans 1, 3
Among older individuals with CKD, diastolic BP is often low due to increased arterial stiffness, making aggressive systolic BP lowering potentially problematic and requiring careful consideration of treatment goals 1, 3
Intensive BP lowering in advanced CKD may accelerate the need for kidney replacement therapy in some patients, highlighting the importance of weighing the benefits and risks of treatment 1, 3

Avoid dual RAAS blockade (combining ACE inhibitor and ARB) as this increases adverse events without additional benefit, emphasizing the importance of careful medication management 2
Further GFR decline beyond the initial 30% after starting ACE inhibitors/ARBs should be investigated for other causes such as volume contraction, nephrotoxic agents, or renovascular disease, highlighting the need for close monitoring and prompt intervention 7
Masked hypertension may occur in up to 30% of patients with CKD and is associated with worse outcomes, highlighting the importance of home or ambulatory BP monitoring to ensure accurate diagnosis and treatment 7